VolitionRX Analyst Ratings
VolitionRX Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
10/30/2023 | 469.62% | EF Hutton | → $4.5 | Initiates Coverage On | → Buy |
08/16/2023 | 153.16% | Cantor Fitzgerald | $3 → $2 | Maintains | Overweight |
06/01/2023 | 659.49% | EF Hutton | → $6 | Assumes | → Buy |
03/16/2023 | 659.49% | EF Hutton | → $6 | Reiterates | → Buy |
02/01/2023 | — | Benchmark | Downgrades | Buy → Hold | |
12/19/2022 | 659.49% | EF Hutton | → $6 | Initiates Coverage On | → Buy |
08/23/2022 | 532.91% | Maxim Group | $8 → $5 | Maintains | Buy |
08/15/2022 | 659.49% | Aegis Capital | $9 → $6 | Maintains | Buy |
11/16/2021 | 1039.24% | Aegis Capital | $10 → $9 | Maintains | Buy |
03/10/2021 | 912.66% | Cantor Fitzgerald | → $8 | Initiates Coverage On | → Overweight |
01/25/2021 | 1165.82% | Aegis Capital | $8 → $10 | Maintains | Buy |
08/19/2020 | 912.66% | Aegis Capital | $10 → $8 | Maintains | Buy |
05/06/2020 | 1165.82% | Aegis Capital | → $10 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
---|---|---|---|---|---|
2023年10月30日 | 469.62% | EF Hutton | →$4.5 | 開始承保 | →購買 |
08/16/2023 | 153.16% | 康託·菲茨傑拉德 | $3→$2 | 維護 | 超重 |
06/01/2023 | 659.49% | EF Hutton | →$6 | 假設 | →購買 |
03/16/2023 | 659.49% | EF Hutton | →$6 | 重申 | →購買 |
02/01/2023 | - | 基準 | 評級下調 | 購買→Hold | |
2022年12月19日 | 659.49% | EF Hutton | →$6 | 開始承保 | →購買 |
2022年08月23日 | 532.91% | Maxim集團 | $8→$5 | 維護 | 買 |
2022年08月15日 | 659.49% | 宙斯盾資本 | $9→$6 | 維護 | 買 |
2021年11月16日 | 1039.24% | 宙斯盾資本 | $10→$9 | 維護 | 買 |
03/10/2021 | 912.66% | 康託·菲茨傑拉德 | →$8 | 開始承保 | →超重 |
2021/01/25 | 1165.82% | 宙斯盾資本 | $8→$10 | 維護 | 買 |
2020年08月19日 | 912.66% | 宙斯盾資本 | $10→$8 | 維護 | 買 |
05/06/2020 | 1165.82% | 宙斯盾資本 | →$10 | 開始承保 | →購買 |
What is the target price for VolitionRX (VNRX)?
VolitionRX(VNRX)的目標價是多少?
The latest price target for VolitionRX (AMEX: VNRX) was reported by EF Hutton on October 30, 2023. The analyst firm set a price target for $4.50 expecting VNRX to rise to within 12 months (a possible 469.62% upside). 6 analyst firms have reported ratings in the last year.
VolitionRX(美國證券交易所代碼:VNRX)的最新目標價是由EF Hutton於2023年10月30日報道的。這家分析公司將目標價定為4.5美元,預計VNRX將在12個月內上漲至(可能上漲469.62)。6家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for VolitionRX (VNRX)?
VolitionRX(VNRX)的最新分析師評級是多少?
The latest analyst rating for VolitionRX (AMEX: VNRX) was provided by EF Hutton, and VolitionRX initiated their buy rating.
對VolitionRX(美國證券交易所代碼:VNRX)的最新分析師評級是由EF Hutton提供的,VolitionRX啟動了他們的買入評級。
When is the next analyst rating going to be posted or updated for VolitionRX (VNRX)?
VolitionRX(VNRX)的下一次分析師評級將於何時發佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of VolitionRX, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for VolitionRX was filed on October 30, 2023 so you should expect the next rating to be made available sometime around October 30, 2024.
分析師在進行了廣泛的研究後得出了股票評級,其中包括查閱公開財務報表,與VolitionRX的高管和客戶交談,以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次,所以你每年應該會得到每家公司每家公司的4個評級。VolitionRX的上一次評級是在2023年10月30日提交的,所以你應該預計下一次評級將在2024年10月30日左右的某個時候提供。
Is the Analyst Rating VolitionRX (VNRX) correct?
分析師對VolitionRX(VNRX)的評級正確嗎?
While ratings are subjective and will change, the latest VolitionRX (VNRX) rating was a initiated with a price target of $0.00 to $4.50. The current price VolitionRX (VNRX) is trading at is $0.79, which is within the analyst's predicted range.
雖然評級是主觀的,並會發生變化,但最新的VolitionRX(VNRX)評級是以0.00美元至4.50美元的目標價啟動的。VolitionRX(VNRX)目前的交易價格為0.79美元,在分析師的預測區間內。
譯文內容由第三人軟體翻譯。